Free Trial

Chardan Capital's Rating of Minerva Neurosciences on 12/2/2019

On December 2, 2019, Chardan Capital updated its outlook on Minerva Neurosciences (NASDAQ:NERV) with the action "Reiterated Rating", keeping a "Buy" rating. MarketBeat All Access subscribers can view the full ratings details, 12-month ROI, historical price target changes, and related news coverage on this page.

unlock icon  Upgrade to MarketBeat All Access

This premium research tool is available to MarketBeat All Access subscribers only. Log in to your account or sign up below.

Already have an account? Log in here.